-
ABOUT USSSY Group Limited is a large high-tech pharmaceutical enterprise with coordinated development of R&D and industrialization in multiple fields such as new drugs, generic drugs, characteristic APIs
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the development mode of “production, learning, research, and application” of multi-disciplinary integration and multi-directional combination.
-
RECRUITIt has established high-level innovation platforms such as engineering laboratory and technology research center jointly with Chinese Academy of Sciences, and now has nearly 400 high-level talents in drug research, analysis and clinical research.
-
SUBSIDIARIESThe company has a diversified business development pattern of R&D, production and export of new drugs, generic drugs, characteristic APIs, advanced finished pharmaceutical products, biological preparations and pharmaceutical packaging materials.
-
CONTACTWe will continue to strengthen innovation-driven development, will vigorously encourage the integration of production and research, strengthen and improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs
Shijiazhuang Sihua Pharmaceutical Obtains CNAS Laboratory Accreditation Certificate
Category:
发布时间：2024-11-16
【概要描述】
Recently, the laboratory of Shijiazhuang Sihua Pharmaceutical Co., Ltd. was awarded an accreditation certificate by the China National Accreditation Service for Conformity Assessment (CNAS), signifying that the laboratory’s hardware facilities, testing capabilities, and management standards have now met international accreditation criteria and that the company has entered a fast track of scientific, standardized, and internationally aligned development.
Recently, the laboratory of Shijiazhuang Sihua Pharmaceutical Co., Ltd. was awarded an accreditation certificate by the China National Accreditation Service for Conformity Assessment (CNAS), signifying that the laboratory’s hardware facilities, testing capabilities, and management standards have now met international accreditation criteria and entered a fast track of scientific, standardized, and internationally aligned development.
According to reports, the China National Accreditation Service for Conformity Assessment (CNAS) is an accreditation body established and designated by the Certification and Accreditation Administration of the People’s Republic of China (CNCA), responsible for the unified implementation of accreditation for certification bodies, laboratories, inspection bodies, and other relevant organizations. Currently, China’s national accreditation system has been integrated into the international mutual recognition framework and enjoys a prominent position within it. Quality inspection bodies accredited by CNAS can issue reports bearing the CNAS mark within the scope of their accreditation, which are mutually recognized in more than 150 countries and regions under the framework of the International Laboratory Accreditation Cooperation. This “one certificate, global recognition” arrangement provides greater convenience and broader market access for products seeking to enter overseas markets.
“Obtaining CNAS accreditation marks a pivotal step for the company on the path toward internationally standardized laboratory management,” said the head of the Group’s Quality Management Center. In recent years, while continuously upgrading and expanding the laboratory’s state-of-the-art, comprehensive testing equipment, the Group has also actively introduced and implemented an advanced LIMS digital laboratory information management system. By recruiting high-caliber technical talent and rigorously managing the laboratory environment and operational standards, the Group has steadily refined and deepened its quality standard evaluation framework, continually enhancing the precision and reliability of its quality testing and management processes. This has effectively ensured the accuracy and trustworthiness of every pharmaceutical test result.
The Group’s head stated that obtaining the CNAS laboratory accreditation certificate represents another significant achievement in the Group’s efforts to strengthen quality management and technical capabilities. Moving forward, the Group will take this milestone as an opportunity to continuously enhance its capacity for technological innovation and its level of quality management, accelerate the pursuit of higher-level international product certifications, consistently meet the requirements of the company’s global expansion, and strive to contribute to the innovative, high-quality development of both the enterprise and Shijiazhuang’s biopharmaceutical industry.
Keywords:
Recommended News
Share to
SERVICE HOTLINE
Address: Shimen Building, No. 8 Xingye Street, Shijiazhuang Economic and Technological Development Zone
Tel.: +86-311-67167130
Email: office@sjzsiyao.com
Mobile site
E code
Non-Commercial (Filing) – 2025-0091